A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function
|
|
- Joshua Dixon
- 8 years ago
- Views:
Transcription
1 Original Article TESTOSTERONE GEL NORMALIZES ANDROGEN LEVELS T.A. McNICHOLAS et al. Men s health has become so important that it is now virtually a political issue. With advancing age, testosterone levels decrease and this has an effect on body composition, mood, and sexual function. There have been many attempts to counteract what has now become known as the andropause. Many questions need to be answered. For example, does the serum testosterone level need to be restored to normal? Is it always abnormal in older men? Will this restoration to normal levels enhance well being without incurring other risks? Are gels more effective than patches? Not all of these questions can be answered in a single paper, but some of them are. However, the big question remains: will men s health continue to be of major importance, and will testosterone replacement be generally accepted? A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function T.A. McNICHOLAS, J.D. DEAN*, H. MULDER, C. CARNEGIE and N.A. JONES Department of Urology, Lister Hospital, Stevenage, Herts, *The Salisbury Clinic, Plymouth, Devon, Osteosupport, Rotterdam, the Netherlands and Auxilium UK Ltd, Brinkworth, Wiltshire, UK Accepted for publication 3 October 2002 OBJECTIVE To compare the safety and efficacy of two doses of a new testosterone gel formulation (Testim, Auxilium Pharmaceuticals, Inc., Norristown, PA, USA) to a permeation-enhanced testosterone patch (Andropatch, GlaxoSmithKline, UK) for treating men with confirmed low serum testosterone levels, and associated signs and symptoms of hypogonadism. PATIENTS AND METHODS In all, 208 men were randomized and treated at 29 centres in Denmark, Germany, Netherlands, Sweden and the UK. The men were treated for 90 days, and the pharmacokinetics and treatment effectiveness of Testim at two doses (50 and 100 mg/day, delivering a daily dose of 5 and 10 mg testosterone, respectively) and Andropatch (2 2.5 mg patches, each delivering 2.5 mg testosterone and containing 12.2 mg of testosterone) were compared. Pharmacokinetic profiles were obtained, body composition measured, and mood and sexual function data recorded. mean increases from baseline to 90 days in testosterone were 12.41, 6.54 and 3.82 nmol/l for Testim 100 and 50 mg/day and the Andropatch, respectively. Both doses of Testim significantly improved positive and negative mood over baseline; Andropatch did not. All three treatments increased lean body mass, and the higher dose of Testim produced a significant decrease in percentage body fat. At all sample times both doses of Testim significantly improved sexual performance, sexual motivation, sexual desire and spontaneous erections. Andropatch provided insignificant improvements from baseline at all sample times for sexual desire, an inconsistent improvement in sexual motivation, but no effect on spontaneous erections. These results are similar to those previously reported for testosterone replacement therapy in hypogonadal men, suggesting that normalization of serum testosterone restores sexual function. However, the present data suggest that higher serum testosterone levels may further improve sexual function. Gel treatment was well tolerated, while patch treatment produced higher rates of application-site reactions and study discontinuation. RESULTS Testim produced dose-dependent improvements in all pharmacokinetic variables compared with Andropatch. The CONCLUSION The favourable pharmacokinetic profile and treatment outcome, combined with the enhanced tolerability of Testim, suggest that 2003 BJU INTERNATIONAL 91, doi: /j x 69
2 T.A. McNICHOLAS ET AL. this new gel formulation is a safe and effective treatment in men with low serum testosterone levels and associated signs and symptoms of hypogonadism. KEYWORDS levels of testosterone with less fluctuation than with Androderm and had significant clinical benefits over placebo for muscle mass and sexual function variables. Testim was also better tolerated than Androderm because it produced fewer adverse skin reactions [9]. testosterone (i.e. fatigue, decreased muscle mass, reduced libido, and reduced sexual functioning that was not mechanical). Except for hypogonadism, the men were generally in good health. All men signed an informed consent form previously approved by an Independent Ethics Committee. testosterone, clinical trial, male, gel formulation, hypogonadism, sexual function, body composition INTRODUCTION It has been previously shown that testosterone levels decrease with ageing and that the decrease in testosterone below levels considered physiologically eugonadal for young mature men has a deleterious effect on sexual characteristics, sexual behaviour, energy levels, mood, muscle development and possibly bone density. Restoring testosterone levels ameliorates these deleterious affects [1 5]. The therapeutic methods currently available in Europe for replacing testosterone in the hypogonadal state are intramuscular injections, oral formulations or the transdermal patch. Each of these methods of testosterone supplementation have deficiencies; intramuscular injections are painful, require repeated office visits for injection, and produces high levels of serum testosterone initially that decline below physiological levels towards the end of the injection cycle. The oral formulations of testosterone have a high first-pass liver metabolism, and certain oral preparations have significant liver toxicity. The transdermal patches, while providing relatively consistent testosterone levels, produce variability in therapeutic testosterone levels over the length of the day, and produce significant skin irritation with prolonged use [6 8]. A unique topical testosterone gel (Testim, Auxilium Pharmaceuticals, Inc., Norristown, PA, USA) was developed to circumvent the shortcomings of the other available forms of testosterone delivery, and to provide consistent therapeutic levels of testosterone therapy. In a multiple-dose, active (2 2.5 mg of testosterone in transdermal patches, Androderm, GlaxoSmithKline, USA) and placebo-controlled study in 406 hypogonadal males, conducted in the USA, Testim at doses of 50 and 100 mg/day provided higher The present study comprised ageing men with low serum testosterone levels ( 10.4 nmol/l) and associated signs and symptoms of hypogonadism. We compared three parallel groups treated with Testim at two doses or Andropatch (GlaxoSmithKline). The study was designed to evaluate and compare the efficacy of transdermal testosterone preparations in normalizing serum testosterone, and ameliorating the signs and symptoms of hypogonadism. PATIENTS AND METHODS In all, 208 men were randomized and treated at 29 centres in Denmark, Germany, the Netherlands, Sweden and the UK, with 70 in each treatment group (Table 1). The men were aged years and had a morning serum testosterone level of 10.4 nmol/l at screening (measured at a central laboratory) and one or more symptoms of low TABLE 1 The characteristics of the men The study was designed as a randomized, multidose, multicentre, active controlled study. The three daily treatments under study were Testim 50 and 100 mg (delivering a daily dose of 5 mg and 10 mg testosterone, respectively), and a transdermal testosterone patch (Andropatch, two patches each delivering 2.5 mg testosterone and containing 12.2 mg). The Testim treatments were doubleblinded by using a matched placebo gel but was open-label for the Andropatch group. All study drug treatments were applied in the morning; repeat applications were administered at the same time of day for the duration of the study. On the day before starting treatment the men had a baseline 24-h profile for serum testosterone, free testosterone and dihydrotestosterone (DHT), consisting of serum samples taken at 08.00, 10.00, and hours, the 24 h sample being taken at hours on the first day, immediately Variable Testim, mg/day Andropatch Total Demographics Number of men Mean (SD): Age, year 59.0 (9.5) 56.7 (10.3) 57.9 (10.8) 57.9 (10.2) Height, cm 177 (6) 178 (7) 178 (7) 177 (7) Weight, kg 85.9 (12.1) 88.1 (11.6) 89.2 (12.3) 87.7 (12.0) Body mass index 27.7 (3.6) 27.9 (4.0) 28.3 (3.6) 28.0 (3.7) Testosterone, nmol/l 7.95 (2.17) 7.92 (2.45) 7.90 (2.23) 7.92 (2.28) IPSS 4.8 (4.9) 5.3 (4.7) 4.8 (5.4) 5.0 (5.0) PSA, ng/ml 1.17 (1.23) 1.18 (1.22) 1.40 (1.37) 1.25 (1.27) % of men by PSA level: > Cause of hypogonadism, n Primary Secondary *Ageing, % *Normogonadotrophic, % *% of total by treatment group; distribution by cause is shown only if it occurred in >5% of men BJU INTERNATIONAL
3 TESTOSTERONE GEL NORMALIZES ANDROGEN LEVELS before the first dose of study drug. At 30, 60 and 90 days, the 24-h profile was repeated for the three forms before dosing and at 2, 4, 8 and 24 h after the study drug was administered. The prostate status was evaluated at screening (PSA levels only), and the day before and 90 days after treatment by PSA levels, the IPSS and a DRE. Body composition, i.e. lean body mass, fat mass and percentage of body fat (%fat), and bone mineral density of the L1 L4 section of the lumbar spine were measured by dual-energy X-ray absorptiometry at 1, 60 and 90 days. The sexual function and mood questionnaires were recorded daily for 14 days before starting the drug and then daily for 7 days before the 30, 60 and 90 days assessment. Skin irritation was examined using a standardized, discrete scoring system before dosing (day 1) and at 30, 60 and 90 days afterward. The medical history and physical examinations were conducted and all adverse events recorded at each visit. The skin irritation scoring at the application site was as follows: 0, no erythema; 1, minimal erythema; 2, moderate erythema with sharply defined borders; 3, intense erythema with or with no oedema; 4, intense erythema with oedema and blistering. Sexual functioning and mood assessments were based on a questionnaire that had previously been validated for assessing sexual function and mood, and used previously for evaluating the effects of testosterone gel on sexual function and mood [1]. The questionnaire elicited information on sexual function, i.e. performance, motivation, spontaneous erections, desire, enjoyment (with and without a partner), and satisfaction with erection duration and percentage of full erection. The men also rated positive mood (alert, full of energy, friendly, well, or good) and negative mood (angry, irritable, sad or depressed, tired, nervous). Serum testosterone and derivatives were all measured using validated radioimmunoassay kits (Diagnostic Products Corp., Los Angeles, CA for testosterone and free testosterone, and Diagnostic Systems Laboratories, Webster, TX for DHT). STATISTICS The 24-h pharmacokinetic profiles for testosterone and DHT were summarized by average, minimum and maximum concentrations (C avg, C min and C max ) after dosing. The changes from baseline to 30, 60 and 90 days in C min, C avg, and C max were analysed using an analysis of covariance (ANCOVA) with the baseline value as the covariate and treatment group as the factor. Similar analyses were used for the change from baseline in sexual function, mood and body composition, and for the clinical laboratory variables at 30, 60 and 90 days. Treatment-emergent adverse events were compared using Fisher's exact test. Skin irritation at each sample times was analysed using the Wilcoxon rank-sum test. At 30, 60 and 90 days both the 50 and 100 mg Testim groups were compared separately with the Andropatch group using an α level of 0.05; all comparisons for safety variables also used this level. The changes from baseline in sexual function, body composition and mood were also analysed for non-zero differences within each treatment group, based on the adjusted least squares means from the ANCOVA model. RESULTS In all, 208 men were randomized, with 68, 72 and 68 in the Testim 50, Testim 100 mg/day and Andropatch groups, respectively (Table 1). The baseline characteristics were comparable across all three groups. The causes of hypogonadism were primarily attributed to the secondary causes of ageing and normogonadotrophic hypogonadism changes (Table 1). A significant proportion of enrolled men completed the 90-day study (93% and 97% in the Testim 50 and 100 mg/day groups, respectively, and 79% in the Andropatch group). The primary reason for the higher rate of discontinuation in the Andropatch group was adverse events (13%) with most being related to skin irritation at the patch site. Dosing compliance over the completed dosing periods ranged from 96% (Andropatch) to 97% (Testim 100 mg/day). ANDROGEN LEVELS Testim increased serum testosterone levels more than did Andropatch and generally in a dose-dependent manner (Table 2). Consistently throughout the study, Testim 100 mg/day increased C avg, C min and C max more than 50 mg/day and Andropatch. At 90 days the mean change from baseline with the 100 mg/day Testim in testosterone C avg was over three times greater than that with Andropatch (P < 0.001) and about double the increase seen with the 50 mg/day Testim (P < 0.05). The results at 30 and 60 days were consistent with those at 90 days. The mean changes in DHT (C avg, C min and C max ) from baseline at 90 days are also shown in Table 2. Testim had similar effects on DHT as on testosterone, with significant consistent increases from baseline throughout the study and in a dose-dependent manner. Conversely, treatment with Andropatch produced a relatively small increase in all three variables for DHT. At 90 days the change in DHT C avg was greater with 100 and 50 mg/day Testim than with Andropatch (P < for both comparisons, Table 2). The results from 30 and 60 days were consistent with those at 90 days. The data for free testosterone are also shown in Table 2 and were comparable with those for testosterone. Testim increased free testosterone levels more than did the Andropatch and in a dose-dependent manner; the mean change in C avg at 90 days with 100 mg/day Testim was more than twice that with 50 mg/day Testim (P < 0.001) and more than three times that with Andropatch (P < 0.001). The results at 30 and 60 days were consistent with those at 90 days. BODY COMPOSITION For lean body mass, at 90 days, as at 60, there were significant within-treatment group changes from baseline for all three treatments. The only other significant withintreatment group change from baseline was in the 100 mg/day Testim group for %fat (P < 0.01), where there was a reduction of 0.12%. The increase in lean body mass in the 100 mg/day Testim group was 2.5% (1.5 kg). The 90 day body composition results are also shown in Table 2. Not surprisingly in a 90-day study, there were no statistically significant changes in bone mineral density within any of the three treatment groups. MOOD Although there were no statistically significant treatment differences among the three groups the 100 mg/day Testim group had significant increases from baseline in positive mood at all samples times, while the 50 mg/day Testim group had significant increases at 30 and 90 days. The Andropatch group had no statistically significant changes from baseline at any time. The alleviation of negative mood, as shown by a reduction in negative mood scores, was consistent in the 50 mg/day Testim group at all times from baseline and for the 100 mg/ day group at 60 and 90 days. In contrast there 2003 BJU INTERNATIONAL 71
4 T.A. McNICHOLAS ET AL. was no statistically significant within-group change for Andropatch at any time. There were significant differences between treatment groups at 90 days in favour of Testim over the Andropatch (P < 0.05). SEXUAL FUNCTION For those sexual function variables assessed the results showed that all treatment groups had a significant improvement in sexual function throughout the study, although there were few significant differences between treatment groups at any time. At 90 days there were significant improvements within treatments from baseline for all three groups in sexual motivation, sexual desire and sexual performance (Table 2). While there were no statistically significant differences among treatment groups, both Testim groups had a statistically significant within-treatment improvement in spontaneous erections at all times from baseline (P < 0.05). Andropatch produced no statistically significant within-treatment changes from baseline at any time. Men treated with Testim had about twice the incidence of spontaneous erections at 30 and 60 days than at baseline. Men treated with Testim had a consistent improvement in sexual motivation throughout the 90-day period, with significant differences from baseline at all times, but the Andropatch group had a less consistent improvement, with no differences from baseline at 60 days. Men in all three groups had a consistent and significant increase in sexual desire throughout the study. Men treated with Testim generally had a greater and more consistent improvement in sexual performance than those treated with Andropatch. At 30 days there was a significant increase with 100 mg/day Testim group vs the Andropatch (P < 0.05). The change from baseline at 90 days is shown in Table 2, with significant and clinically meaningful improvements of 50%, 38% and 33% in the 100, 50 mg/day Testim and Andropatch groups, respectively (P < 0.001, < 0.05 and < 0.05). SAFETY Overall, the incidence of experiencing one or more treatment-emergent adverse events was similar in the Testim groups, but was about twice as high in the Andropatch group, at 35% for 50 and 29% for 100 mg/day TABLE 2 The baseline values and change ( ) at 90 days for serum testosterone, DHT, sexual function scores and body composition variables Mean (SD) variable Testim, mg/day Andropatch Testosterone, nmol/l C avg 7.84 (3.25) 7.80 (3.35) 8.73 (3.17) C min 6.34 (2.85) 6.42 (3.00) 6.90 (2.55) C max 9.98 (3.85) 9.66 (4.12) (3.78) C avg 6.54 (8.62) (12.56) 3.82 (4.39) C min 2.98 (5.64)* 7.14 (8.64) 0.35 (3.55) C max (22.85) (22.27) * 8.23 (7.76) DHT, nmol/l C avg 0.50 (0.23) 0.49 (0.27) 0.52 (0.22) C min 0.37 (0.20) 0.35 (0.20) 0.38 (0.18) C max 0.66 (0.28) 0.63 (0.33) 0.67 (0.30) C avg 0.91 (0.94) 1.39 (1.16) 0.03 (0.25) C min 0.67 (0.76) 1.04 (0.93) < 0.01 (0.20) C max 1.17 (1.35) 1.85 (1.59) 0.05 (0.34) Free testosterone, pmol/l C avg (13.41) (13.41) (12.34) C min (11.08) (11.61) (9.02) C max (17.01) (17.68) (14.38) C avg (32.09) (48.50) (18.21) C min 9.14 (17.48) (33.57) 2.06 (13.42) C max (79.19) (81.92)* (33.54) Sexual function scores: Spontaneous erection (mean/week) 0.8 (1.0) 0.8 (1.1) 0.9 (1.0) 0.6 (1.4) 0.5 (1.4) 0.3 (1.2) Motivation (mean/week) 1.5 (1.4) 1.5 (1.3) 1.3 (1.1) 0.4 (1.2) 0.4 (1.3) 0.5 (1.4) Desire (mean/day) 1.6 (1.1) 1.9 (1.4) 1.8 (1.2) 0.8 (1.0) 0.7 (1.4) 0.5 (1.2) Performance (mean/week) 0.8 (0.9) 0.8 (1.0) 0.9 (1.0) 0.3 (1.0) 0.4 (0.9) 0.3 (1.0) Body composition: Lean body mass 57.4 (11.3) 57.2 (11.4) 58.5 (11.7) 0.9 (1.8) 1.5 (1.7) 1.0 (1.9) Fat mass 24.1 (10.9) 26.2 (11.3) 26.6 (13.2) 0.1 (1.8) 0.2 (1.5) 0.1 (2.0) Percentage fat 28.2 (11.9) 30.0 (11.6) 29.5 (12.5) 0.4 (2.0) 0.7 (1.3) 0.3 (1.9) Significant vs Andropatch *P < 0.05, < 0.001; significant for Testim 50 vs 100 mg/day, P <0.05, < 0.001; significant within-treatment group change from baseline P <0.05, < Testim, and 63% for the Andropatch. Whilst treatment in the Testim groups was relatively well-tolerated over the 90-day period, the Andropatch treated men had a substantially higher rate of adverse events. Those most commonly reported were erythema, irritation and reactions at the application site. In the Andropatch group there was a higher frequency of withdrawal from the study because of adverse events, i.e. 13% with Andropatch and 4% in the 50 and none in the 100 mg/day Testim groups. All of the discontinuations for adverse events in the Andropatch group were caused by local tolerability problems associated with the patch application site. LABORATORY ANALYSES The incidence of clinically notable laboratory values was low for all treated men. There were small decreases in total cholesterol and highdensity lipoprotein (HDL) which were doserelated; there were significant differences BJU INTERNATIONAL
5 TESTOSTERONE GEL NORMALIZES ANDROGEN LEVELS FIG. 1. The distribution of men with positive application-site irritation scores at 30 (open bars), 60 (green bars) and 90 days (red stippled bars). The scoring system is detailed in the text. There were significant differences (P < 0.001) for each of the Testim vs Andropatch comparisons at each time. between the 100 and the 50 mg/day Testim dose (P < 0.05) but not compared with Andropatch. There was no significant effect on the total cholesterol/hdl ratio for any of the three treatments. Increases in haemoglobin, haematocrit, and red blood cells (RBCs) are known pharmacological effects of testosterone [1,5]. Consistent with this, men in the 100 mg/day Testim group had statistically significant increases from baseline to 90 days in haematocrit and haemoglobin, compared with both the 50 mg/day Testim and Andropatch groups (P < for haematocrit and RBC count, P < 0.01 for haemoglobin, both group comparisons). The effects with Andropatch treatment were consistently smaller than those with Testim, reflecting the lower mean serum testosterone levels with Andropatch treatment. There were also statistically significant mean changes for eosinophils and basophils, but the changes were minor and of no apparent clinical significance. The mean changes in PSA at 90 days were relatively small; they were >4.0 ng/ml at least once during treatment in 3%, 4% and 3% of men in the 50 and 100 mg/day Testim and Andropatch groups, respectively. These PSA changes were consistent with the known effects of testosterone therapy [1,5,9]. Most increases in PSA were <1 ng/ml and levels stayed below that considered to be abnormal (4.0 ng/ml). The changes from baseline IPSS were very small and the incidence of men having worse findings on a DRE was low. No variables provided evidence of clinically relevant treatment-related effects or differences. SKIN IRRITATION Number of men Figure 1 shows the frequency distribution of men with positive skin irritation scores. As Score Testim Testim Andropatch 50 mg/day 100 mg/day 5 mg/day noted, the scoring system was based on a five-point categorical series; overall, the Testim-treated groups had a very low incidence of skin irritation. Doubling the dose of Testim (to 100 mg/day) did not increase the incidence of skin irritation events. In comparison, the Andropatch group had a substantially higher incidence of skin irritation, with 47% of men reporting irritation at 30 days and 53% reporting it at 90 days. Furthermore, the reported irritation was more severe, with many men categorizing it as moderate to intense. DISCUSSION This study showed that testosterone gel was superior to the marketed comparison Andropatch; Testim 100 mg/day was better than Andropatch for normalizing serum testosterone levels. Furthermore, there was a clear dose response, in that Testim 100 mg/day was better than 50 mg/day for normalizing serum testosterone levels. Comparable results were obtained with serum levels of DHT and free testosterone. While both doses of Testim produced similar statistically significant increases over baseline in lean body mass, the higher dose of Testim also produced a statistically significant decrease over baseline in %fat. Both doses of Testim gave statistically significant improvements in positive and negative mood over baseline; there were no similar effects on mood with Andropatch. The therapeutic effect was further substantiated because both doses of Testim improved the sexual variables, improving sexual performance throughout the study at statistically significant levels, whereas Andropatch had no effect at 30 days. At all three times during the study, both doses of Testim produced significant improvements from baseline in sexual performance, sexual motivation, sexual desire, and spontaneous erections. Such improvements after restoring serum testosterone to normal levels are likely to be clinically meaningful in older men with low testosterone levels. Andropatch produced inconsistent improvements over baseline in sexual motivation, significant improvements at all times for sexual desire, but no effect at any time on spontaneous erections. The men had potentially beneficial and known pharmacological class effects of androgens, i.e. raising the levels of haematocrit, haemoglobin and RBCs. There were small mean increases in PSA in all groups, but no effect on the IPSS. There were small but notable dose-related decreases in total cholesterol and HDL with Testim, and no significant changes in the total cholesterol/ HDL ratio. There were more application-site reactions with Andropatch than with Testim; more men treated with Andropatch discontinued treatment because of these reactions than with Testim. Both doses of Testim improved mood, lean body mass, sexual performance, sexual desire, sexual motivation and spontaneous erection. Finally, men complied better with Testim as a result of the lower incidence of dermal irritation, which is an important advantage for a potentially longterm therapy. This study confirms that Testim is a viable and better alternative to the currently available therapeutic methods in Europe for testosterone replacement. ACKNOWLEDGEMENTS This study was sponsored by Auxilium UK Limited. Auxilium UK Limited thanks the following investigators for their participation and contribution to this clinical study. Dr M. Callander, Dr J. Dean, Dr G. Hackett, Dr M. Kirby, Dr A. Levy, Mr T. McNicholas, Dr D. Price, Dr R. Quinton, Dr T. Robinson, Dr J. Tomlinson (UK); Dr H. Bulk, Dr B. Jan de Boer, Dr J. Jonker, Dr H. Mulder, Dr P. van der Graaff (Netherlands); Dr U. Ekstrom, Dr M. Haggmann, Dr J. Oldbring (Sweden); Dr T. Gerstenberg, Dr J. Otto Jorgensen, Dr J. Poulsen (Denmark); Dr P. Malsy-Mink, Prof H. Porst, Dr D. Quast, Dr B. Rosenkranz, Prof W. B. Schill, Dr A. von Keitz, Dr P. Weitz, Dr R. Zillmann (Germany). REFERENCES 1 Wang C, Swerdloff R, Iranmanesh A et al. Transdermal testosterone gel improves 2003 BJU INTERNATIONAL 73
6 T.A. McNICHOLAS ET AL. sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: Arver S, Dobs AS, Meikle AW et al. Longterm efficacy and safety of a permeationenhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997; 47: Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: Tenover JL. Testosterone and the aging male. J Androl 1997; 18: Jordan WP, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther 1998; 20: Jordan WP. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non-scrotal transdermal systems. Am J Contact Dermatol 1997; 8: Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthanate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84: Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. Testim normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; in press Correspondence: J.D. Dean, The Salisbury Clinic, 43 Salisbury Road, Plymouth, Devon PL4 8QU, UK johndean@netcomuk.co.uk Abbreviations: DHT, dihydrotestosterone; %fat, percentage of body fat; ANCOVA, analysis of covariance; HDL, high-density lipoprotein; RBCs, red blood cells BJU INTERNATIONAL
Prevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus
Prevalence Diagnosis and Treatment of Hypogonadism in Primary Care Practice by Culley C. Carson III, MD, Boston University Medical Campus Hypogonadism is defined as deficient or absent male gonadal function
More informationTestosterone Treatment in Older Men
Testosterone Treatment in Older Men J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships to disclose.
More informationTestosterone in Old(er) Men
Testosterone in Old(er) Men Disclosure Information J. Bruce Redmon, M.D. Associate Professor Division of Endocrinology I have no financial relationships to disclose. I will not discuss off label use and/or
More informationTestosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone
More informationCommittee Approval Date: October 14, 2014 Next Review Date: March 2015
Medication Policy Manual Topic: Testosterone replacement therapy products: - Androderm, - Axiron, - Fortesta, - Striant, - Testim Gel, - Natesto, - Vogelxo Policy No: dru297 Date of Origin: March 15, 2013
More informationHypogonadism and Testosterone Replacement in Men with HIV
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hypogonadism and Testosterone Replacement in Men with HIV Stephanie T. Page, MD, PhD Robert B. McMillen Professor in Lipid Research, Associate Professor of
More informationFocus. Andropause: fact or fiction? Introduction. Johan Wilson is an Auckland GP KEY POINTS
1 of 5 Focus Andropause: fact or fiction? Johan Wilson is an Auckland GP Introduction Androgen deficiency in the ageing male, or andropause, is being diagnosed with increased frequency. A growing body
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More informationHormone Replacement Therapy For Men Consultation Information. Round Rock Jollyville Westlake 512-231-1444 www.urologyteam.com.
Hormone Replacement Therapy For Men Consultation Information Round Rock Jollyville Westlake 512-231-1444 www.urologyteam.com Rev 05/13 Table of Contents Biological Aging and Hormones 2 As we age.... 3
More informationCOULD IT BE LOW TESTOSTERONE?
COULD IT BE LOW TESTOSTERONE? By Dr. Lauren M. Bramley For thousands of years women have been recognized for their sensitivity to hormones. PMS, post partum depression, menopause have long been plights
More informationTestosterone & Testosterone Replacement Therapy
your PR.i.VATES Testosterone & Testosterone Replacement Therapy www.yourprivates.org.uk CONTENTS TESTOSTERONE & TRT Contents Introduction 3 Purposes of testosterone 4 How will I be affected by an orchidectomy?
More informationAging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone
Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent
More informationMedication Policy Manual
Medication Policy Manual Topic: Non-preferred testosterone replacement therapy products (Androderm, Androgel, Aveed, Axiron, Fortesta, Natesto, Striant, Testim Gel, Testopel, Vogelxo, compounded testosterone
More informationPublic Assessment Report Scientific discussion. Tostrex (Testosterone) SE/H/571/01
Public Assessment Report Scientific discussion Tostrex (Testosterone) SE/H/571/01 This module reflects the scientific discussion for the approval of Tostrex. The procedure was finalised at 2006-04-07.
More informationX-Plain Low Testosterone Reference Summary
X-Plain Low Testosterone Reference Summary Introduction Testosterone is the most important male sex hormone. It helps the body produce and maintain adult male features. Low levels of testosterone affect
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationtestosterone_pellet_implantation_for_androgen_deficiency_in_men 10/2015 N/A 11/2016 10/2015 This policy is not effective until December 30, 2015
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency_in_men
More informationTestosterone Therapy for Women
Testosterone Therapy for Women The Facts You Need Contents 2 INTRODUCTION: The Facts You Need... 3-4 CHAPTER 1: Testosterone and Women... 5-9 CHAPTER 2: Testosterone Therapy for Women... 10-14 CONCLUSION:
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationA list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
More informationTalk to your doctor about low testosterone
Talk to your doctor about low testosterone Maybe he doesn t find me attractive any more? Maybe he needs to lose some weight? Maybe he s lost his spark? Bayer Pharma AG Müllerstraße 178 13353 Berlin Germany
More informationTestosterone. Testosterone For Women
Testosterone Testosterone is a steroid hormone. Popular use of the term steroid leads people to believe that it signifies a drug that s illegal and abused by some body builders and other athletes. While
More informationt!k EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE
ACRUX (ACR) - ASX ANNOUNCEMENT 24 NOVEMBER 2014 EUROPEAN MEDICINES AGENCY TESTOSTERONE UPDATE The European Medicines Agency (EMA) released a statement regarding the use of Testosterone Replacement Therapy
More informationHuman Clinical Study for Free Testosterone & Muscle Mass Boosting
Human Clinical Study for Free Testosterone & Muscle Mass Boosting GE Nutrients, Inc. 920 E. Orangethorpe Avenue, Suite B Anaheim, California 92801, USA Phone: +1-714-870-8723 Fax: +1-732-875-0306 Contact
More informationHormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions
Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions IMPORTANCE OF HORMONE BALANCE Importance of Hormone Balance Help you live a long, healthy life Help you
More information2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
More informationTestosterone Replacement Informed Consent. Patient Name: Date:
Testosterone Replacement Informed Consent Patient Name: Date: This form is designed to document that you understand the information regarding Testosterone Replacement Therapy, so that you can make an informed
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationUse Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa
Use Of Testosterone In Men With Prostate Cancer Abraham Morgentaler, MD, FACS Director, Men s s Health Boston Associate Clinical Professor of Urology Harvard Medical School Boston, USA Traditional view:
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM G.R. Dohle (chair), S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationAndrogens and CVD. Brandon Orr- Walker April 2014
Androgens and CVD Brandon Orr- Walker April 2014 Agenda What is normal physiology of Aging? Hypogonadism and disease If some is good is more becer? CVD safety Clinical features of Androgen Deficiency
More informationInformation About Hormonal Treatment for
Information About Hormonal Treatment for Trans Men Leighton J Seal PhD FRCP Consultant Endocrinologist, Gender Identity Clinic, West London Mental Health NHS Trust (Charing Cross) Leighton J Seal 1 Patient
More informationGARY S. DONOVITZ, M.D., F.A.C.O.G.
Sub-Cutaneous Hormone Pellet Therapy- The Comprehensive Treatment to Optimize and Balance Hormones Using the BioTE Method GARY S. DONOVITZ, M.D., F.A.C.O.G. The BioTE method of hormone replacement is a
More informationSevere Irritant Contact Dermatitis Causing Skin Ulceration Secondary to a Testosterone Patch
Case Study TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.45 Severe Irritant Contact Dermatitis Causing Skin Ulceration Secondary to a Testosterone Patch Nathan Lawrentschuk* and Neil Fleshner Division
More informationTESTOSTERONE The Future?
TESTOSTERONE The Future? Martin M. Miner MD Co-Director Men s Health Center The Miriam Hospital Clinical Professor of Family Medicine and Urology Warren Alpert School of Medicine of Brown University Providence,
More informationDeficient testosterone levels in men above 45 years with major depressive disorder an age-matched case control study
Deficient testosterone levels in men above 45 years with major depressive disorder an age-matched case control study A M Dikobe, MB ChB, MMed (Psych) C W van Staden, MB ChB, MMed (Psych), MD, FCPsych,
More information0021-972X/00/$03.00/0 Vol. 85, No. 3 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 3 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal
More informationVaricocele: To Fix or Not to Fix? That is the Question. Edmund S. Sabanegh, MD
Varicocele: To Fix or Not to Fix? That is the Question. Edmund S. Sabanegh, MD Professor and Chairman, Department of Urology, Cleveland Clinic Lerner College of Medicine; Cleveland, Ohio Objectives: Review
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511351:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: CR002353 Johnson & Johnson Pharmaceutical
More informationTestosterone Replacement Therapy and Prostate Risks: Where s the Beef?
Testosterone Replacement Therapy and Prostate Risks: Where s the Beef? Abraham Morgentaler, MD Division of Urology Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts, USA
More informationPrevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy
Prevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy International Society for Sexual Medicine 2014 Presenter: Felipe Borges
More informationFREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
More informationTestosterone Replacement Therapies
Testosterone Replacement Therapies Policy Number: 5.01.23 Last Review: 7/2015 Origination: 7/2015 Next Review: 7/2016 Policy BCBSKC will provide coverage for testosterone replacement therapies when it
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationEndocrine Responses to Resistance Exercise
chapter 3 Endocrine Responses to Resistance Exercise Chapter Objectives Understand basic concepts of endocrinology. Explain the physiological roles of anabolic hormones. Describe hormonal responses to
More informationREVIEW HYPOGONADISM: TREATMENT, SIDE EFFECTS, AND MONITORING. Eric A. Wright, PharmD, BCPS* ABSTRACT TREATMENT
HYPOGONADISM: TREATMENT, SIDE EFFECTS, AND MONITORING Eric A. Wright, PharmD, BCPS* ABSTRACT The basic desire to restore that which makes a man feel vital again is essentially what drives hormone replacement
More informationMale Patient Questionnaire & History
Male Patient Questionnaire & History Name: Today s Date: (Last) (First) (Middle) Date of Birth: Age: Occupation: Home Address: City: State: Zip: E- Mail Address: May we contact you via E- Mail? ( ) YES
More informationTestosterone safety and the prostate
Testosterone safety and the prostate Professor Dr. Ridwan Shabsigh Director, Division of Urology, Maimonides Medical Center, Brooklyn, NY, Professor of Clinical Urology, College of Physicians and Surgeons,
More informationPsoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence
1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationTopical Testosterone Gel for the Treatment of Male Hypogonadism
Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Topical Testosterone Gel for the Treatment of Male Hypogonadism
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationShalender Bhasin, MD. Glenn R Cunningham, MD. Mohit Khera, MD, MBA, MPH
Shalender Bhasin, MD Program Chair Professor of Medicine Boston University School of Medicine Section Chief Division of Endocrinology, Diabetes & Nutrition Boston, MA Glenn R Cunningham, MD Professor of
More informationUnderstanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding
Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement
More informationTestosterone propionate, phenylpropionate, isocaproate and decanoate. Please read this leaflet carefully before you start using SUSTANON 250.
SUSTANON 250 Testosterone propionate, phenylpropionate, isocaproate and decanoate What is in this leaflet Please read this leaflet carefully before you start using SUSTANON 250. This leaflet answers some
More informationTestosterone Replacement Therapy. Craig Ensign, MPAS, PA-C University of Utah School of Medicine Urology Division
Testosterone Replacement Therapy Craig Ensign, MPAS, PA-C University of Utah School of Medicine Urology Division Lecture Outline 1. Anatomy and physiology 2. Definition and etiology 3. Signs and symptoms
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Diagnosis and Assessment Module 2 2 Objectives Identify clinical manifestations and symptoms of hypogonadism Describe components of comprehensive
More information0022-5347/04/1722-0658/0 Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/04/1722-0658/0 Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7 RANDOMIZED STUDY
More informationU.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe Testosterone Report
The Testosterone Report Contents 1. What is Testosterone? 2. Why is Testosterone necessary? 3. Why do my Testosterone Levels decrease? 4. What does low Testosterone cause? 5. How Do I raise my Testosterone?
More informationPROSTATE CANCER. Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American
PROSTATE CANCER 1. Guidelines for Screening Risk Factors Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American High-risk men: Family history of prostate
More informationCONCORD INTERNAL MEDICINE TESTOSTERONE DEFICIENCY PROTOCOL
CONCORD INTERNAL MEDICINE TESTOSTERONE DEFICIENCY PROTOCOL Douglas G. Kelling, Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised April 29, 2012 The information contained in this
More informationMedication Policy Manual. Date of Origin: April 13, 2015. Topic: Testosterone cypionate, testosterone enanthate
Medication Policy Manual Topic: Testosterone cypionate, testosterone enanthate Policy No: dru395 Date of Origin: April 13, 2015 Committee Approval Date: December 11, 2015 Next Review Date: April 2016 Effective
More informationEvaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients
Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential
More informationCompounded Percutaneous Testosterone Gel: Use And Effects in Hypogonadal Men
Compounded Percutaneous Testosterone Gel: Use And Effects in Hypogonadal Men Christopher B. Cutter, MD Background: Current methods of testosterone replacement therapy are limited to fixed-dosage patches
More informationT in Cheek: Buccal Testosterone as a New Treatment for Androgen Deficiency in Men
Reference Section T in Cheek: Buccal Testosterone as a New Treatment for Androgen Deficiency in Men a report by Bradley D Anawalt, MD, F ACP Associate Professor of Medicine, University of Washington and
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationCLS 306 Men and Women s Health Research Paper. Is testosterone therapy a safe and effective approach to treating major depression in adult males?
CLS 306 Men and Women s Health Research Paper Is testosterone therapy a safe and effective approach to treating major depression in adult males? Introduction: Major depressive disorder (MDD) is a debilitating
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationPresenting Genital Symptoms and Physical Signs of Vaginal Atrophy
Sexual Health in the Menopause Presenting Genital Symptoms and Physical Signs of Vaginal Atrophy Symptoms Dryness Itching Burning Dyspareunia Signs on Physical Exam Pale, smooth, or shiny vaginal epithelium
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationUse of Androgens in HIV-Infected Men and Women
Use of Androgens in HIV-Infected Men and Women Steven K. Grinspoon, md Associate Professor of Medicine, Harvard Medical School Director, mgh Program in Nutritional Metabolism Clinical Director, Neuroendocrine
More informationStatistics and Pharmacokinetics in Clinical Pharmacology Studies
Paper ST03 Statistics and Pharmacokinetics in Clinical Pharmacology Studies ABSTRACT Amy Newlands, GlaxoSmithKline, Greenford UK The aim of this presentation is to show how we use statistics and pharmacokinetics
More informationManagement of Erectile Dysfunction and Cardiovascular Disease Princeton III Consensus Recommendations
Management of Erectile Dysfunction and Cardiovascular Disease Princeton III Consensus Recommendations Reptile Dysfunction This is a talk about sex, and contains potentially offensive images Men Avoid Doctors
More informationAbout Andropause (Testosterone Deficiency Syndrome)
About Andropause (Testosterone Deficiency Syndrome) There are many myths, misconceptions and a general lack of awareness about this easily treated hormonal imbalance that research shows affects 20% of
More informationPDL Class: Topical Androgens
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Topical Androgens Month/Year of Review:
More informationTestosterone Supplementation Therapy for Older Men: Potential Benefits and Risks
PROGRESS IN GERIATRICS Testosterone Supplementation Therapy for Older Men: Potential Benefits and Risks David A. Gruenewald, MD*, and Alvin M. Matsumoto, MD* From the *Geriatric Research, Education, and
More informationImpact of exogenous testosterone on mood: A systematic review and meta-analysis of randomized placebo-controlled trials
ANNALS OF CLINICAL PSYCHIATRY ANNALS OF CLINICAL PSYCHIATRY 2014;26(1):19-32 RESEARCH ARTICLE Impact of exogenous testosterone on mood: A systematic review and meta-analysis of randomized placebo-controlled
More informationSERUM. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials
Journal of Gerontology: MEDICAL SCIENCES 2005, Vol. 60A, No. 11, 1451 1457 Copyright 2005 by The Gerontological Society of America Adverse Events Associated With Testosterone Replacement in Middle-Aged
More informationMedication Guide Testim (TĔS tim) CIII (testosterone gel)
Medication Guide Testim (TĔS tim) CIII (testosterone gel) Read this Medication Guide that comes with Testim before you start using it and each time you get a refill. There may be new information. This
More informationBio-Identical Hormone FAQ s
Bio-Identical Hormone FAQ s What are bio-identical hormones? They are derived from a natural plant source and professionally compounded to be biologically identical to human form of estradiol and testosterone.
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationThe submission positioned dimethyl fumarate as a first-line treatment option.
Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an
More informationNDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021015 LABELING SUPPLEMENT AND PMR REQUIRED REMS MODIFICATION NOTIFICATION AbbVie, Inc. Attention: Gennadiy
More informationWhat is the goal after hormone therapy: PSA or testosterone? 삼성서울병원 서성일
What is the goal after hormone therapy: PSA or testosterone? 삼성서울병원 서성일 Huggins & Hodges s study in the 1940s. Testosterone (T) became as a key therapeutic target, and ADT to lower serum T remains standard
More informationBIAsp30 A 1 chieve Tehran 31 July 2015
BIAsp30 A 1 chieve Tehran 31 July 2015 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University Presenter and sponsor duality of
More informationTestosterone for women, who when and how much?
Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More informationOral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationTrial Description. Organizational Data. Secondary IDs
Trial Description Title A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel in patients
More informationRestandol Testocaps, 40mg CAPSULES, SOFT Testosterone undecanoate
RA 1410 IE P7 (ref 3.5) PATIENT INFORMATION LEAFLET Restandol Testocaps, 40mg CAPSULES, SOFT Testosterone undecanoate Read all of this leaflet carefully before you start taking this medicine. Keep this
More information